Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 4
2011 5
2012 5
2013 3
2014 3
2015 3
2016 9
2017 8
2018 10
2019 6
2020 5
2021 5
2022 7
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group. Fenaux P, et al. Among authors: guerci bresler a. Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13. Blood. 2011. PMID: 21753188 Free article. Clinical Trial.
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study.
Stojkov I, Conrads-Frank A, Rochau U, Arvandi M, Koinig KA, Schomaker M, Mittelman M, Fenaux P, Bowen D, Sanz GF, Malcovati L, Langemeijer S, Germing U, Madry K, Guerci-Bresler A, Culligan DJ, Kotsianidis I, Sanhes L, Mills J, Puntscher S, Schmid D, van Marrewijk C, Smith A, Efficace F, de Witte T, Stauder R, Siebert U. Stojkov I, et al. Among authors: guerci bresler a. Blood Adv. 2023 Jun 27;7(12):2772-2783. doi: 10.1182/bloodadvances.2022008360. Blood Adv. 2023. PMID: 36607832 Free PMC article. Clinical Trial.
[NK cells: a major role in the antitumoral immunomodulation in CML].
Toubert A, Turhan A, Guerci-Bresler A, Dulphy N, Réa D. Toubert A, et al. Among authors: guerci bresler a. Med Sci (Paris). 2018 Jun-Jul;34(6-7):540-546. doi: 10.1051/medsci/20183406013. Epub 2018 Jul 31. Med Sci (Paris). 2018. PMID: 30067206 Free article. Review. French.
The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia.
Lebecque B, Bourgne C, Munje C, Berger J, Tassin T, Cony-Makhoul P, Guerci-Bresler A, Johnson-Ansah H, Liu W, Saugues S, Tchirkov A, Vetrie D, Copland M, Berger MG. Lebecque B, et al. Among authors: guerci bresler a. Cancers (Basel). 2022 Sep 27;14(19):4695. doi: 10.3390/cancers14194695. Cancers (Basel). 2022. PMID: 36230624 Free PMC article.
Reply to J. Richter et al.
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, Gardembas M, Etienne G, Réa D, Roy L, Escoffre-Barbe M, Guerci-Bresler A, Tulliez M, Prost S, Spentchian M, Cayuela JM, Reiffers J, Chomel JC, Turhan A, Guilhot J, Guilhot F, Mahon FX. Rousselot P, et al. Among authors: guerci bresler a. J Clin Oncol. 2014 Sep 1;32(25):2823-5. doi: 10.1200/JCO.2014.56.3858. Epub 2014 Jul 28. J Clin Oncol. 2014. PMID: 25071119 No abstract available.
["New treatments for chronic myelogenous leukemia"].
Legros L, Guerci-Bresler A. Legros L, et al. Among authors: guerci bresler a. Rev Prat. 2021 Mar;71(3):245-248. Rev Prat. 2021. PMID: 34161020 French. No abstract available.
[Optimizing the use of bosutinib in patients with chronic-phase chronic myeloid leukemia: Recommendations of a panel of experts from the Fi-LMC (French CML working group)].
Rea D, Cayssials E, Charbonnier A, Coiteux V, Etienne G, Goldwirt L, Guerci-Bresler A, Huguet F, Legros L, Roy L, Nicolini FE. Rea D, et al. Among authors: guerci bresler a. Bull Cancer. 2024 Jan;111(1):87-96. doi: 10.1016/j.bulcan.2023.10.010. Epub 2023 Dec 11. Bull Cancer. 2024. PMID: 38087729 Free article. Review. French.
ENOX2 NADH Oxidase: A BCR-ABL1-Dependent Cell Surface and Secreted Redox Protein in Chronic Myeloid Leukemia.
Baykal-Köse S, Voldoire M, Desterke C, Sorel N, Cayssials E, Johnson-Ansah H, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG. Baykal-Köse S, et al. Among authors: guerci bresler a. Turk J Haematol. 2023 May 29;40(2):101-117. doi: 10.4274/tjh.galenos.2023.2022-0339. Epub 2023 Apr 7. Turk J Haematol. 2023. PMID: 37026766 Free PMC article.
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Mądry K, Lis K, Fenaux P, Bowen D, Symeonidis A, Mittelman M, Stauder R, Čermák J, Sanz G, Hellström-Lindberg E, Langemeijer S, Malcovati L, Germing U, Holm MS, Guerci-Bresler A, Culligan D, Sanhes L, Kotsianidis I, van Marrewijk C, Crouch S, de Witte T, Smith A; EUMDS Registry Participants. Mądry K, et al. Among authors: guerci bresler a. Br J Haematol. 2023 Feb;200(4):451-461. doi: 10.1111/bjh.18542. Epub 2022 Nov 6. Br J Haematol. 2023. PMID: 36335984
Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models.
Muselli F, Mourgues L, Morcos R, Rochet N, Nebout M, Guerci-Bresler A, Faller DV, William RM, Mhaidly R, Verhoeyen E, Legros L, Peyron JF, Mary D. Muselli F, et al. Among authors: guerci bresler a. Cancers (Basel). 2021 Apr 2;13(7):1693. doi: 10.3390/cancers13071693. Cancers (Basel). 2021. PMID: 33918475 Free PMC article.
69 results